Clinical trials: Limited Stage Small Cell Lung Cancer
Small Cell Lung Cancer
Early Versus Late Concurrent Chemoradiation for Limited Stage Small-cell Lung Cancer
The purpose of the study is to evaluate the efficacy and toxicity of different timing of concurrent chemoradiation in the treatment of limited disease status Small-cell lung cancer.
- Trial name
- NCT01125995
- Testing
- early CCRT, late CCRT
- Where
- 2 sites in South Korea
- Volunteers
- 222 people
- Sponsor
- Samsung Medical Center
SCLC, Limited Stage
Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT
This is a retrospective, multi-centre, single arm study to assess the safety and efficacy of receiving Durvalumab in patients with Small Cell Lung Cancer Limited Stage (LS-SCLC) who have not progressed following sequential…
- Trial name
- NCT07309211
- Where
- 4 sites in China
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Background: Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT06694454
- Testing
- azacytidine, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell-Lung, Non-Small Cell Lung Cancer
SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer
A principle objective of the study is to create a validated risk model for treatment selection. This will greatly enhance the ability to counsel patients regarding their specific risks/benefit ratio for surgery or SBRT.
- Conditions
- Carcinoma, Non-Small-Cell-Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
- Trial name
- NCT02562027
- Testing
- European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13, Modified Medical Research Council
- Where
- United States
- Volunteers
- 217 people
- Sponsor
- Washington University School of Medicine
Early Stage Non-small-cell Lung Cancer (Stage 1-2)
Assessment of Ergonomics in 3D vs 2D Thoracoscopic Lobectomy
Video-assisted thoracic surgery (VATS) pulmonary lobectomy is currently widely employed as the first treatment option for surgical management of early stage (stage I-II) non-small-cell-lung-cancer (NSCLC).
- Trial name
- NCT03925103
- Testing
- 3D VATS lobectomy, 2D VATS lobectomy
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- University of Rome Tor Vergata
Non-small Cell Lung Cancer
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
Lung cancer remains the most frequent cause of cancer death in both men and women in the world. Surgical resection using lobectomy with mediastinal lymph node dissection or sampling has been a standard of care for operable early…
- Trial name
- STARS (NCT00840749)
- Testing
- CyberKnife Stereotactic Radiotherapy, Surgery
- Where
- 19 sites in United States, China and 2 more
- Volunteers
- 36 people
- Sponsor
- Accuray Incorporated
Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer
Study to Evaluate NA-NOSE for Monitoring and Detecting Recurrence in Early Stage Lung Cancer
This clinical trial studies nanoscale artificial nose (NA-NOSE) in monitoring response and detecting recurrence after surgery or radiation therapy in patients with stage I or stage II non-small cell lung cancer (NSCLC).
- Conditions
- Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer
- Trial name
- NCT01840150
- Testing
- breath test, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Fox Chase Cancer Center
Non Small Cell Lung Cancer
A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer
The purpose of this trial is to assess how well the combination of pemetrexed with cisplatin can reduce tumor size.
- Trial name
- NCT01165021
- Testing
- Pemetrexed, Cisplatin, Folic Acid
- Where
- 7 sites in Italy
- Volunteers
- 19 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Cancer
Serplulimab Combined With CCRT for LS-SCLC.
Small cell lung cancer(SCLC) has a poor prognosis and a relatively short overall survival time, urgently requiring innovative treatment strategies to improve the prognosis of such patients.
- Trial name
- NCT06295926
- Testing
- Serplulimab
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Peking Union Medical College Hospital
Carcinoma, Non-Small-Cell-Lung Cancer
Neo-Adjuvant Gemcitabine and Cisplatin in Treating Patients With Early Stage of Non Small Cell Lung Cancer
Based on available data, the concept of neo-adjuvant chemotherapy seems to be promising for patients with resectable non-small cell lung cancer. The exploration of new drugs and regimens are warranted.
- Trial name
- NCT00191763
- Testing
- Gemcitabine, cisplatin
- Where
- Turkey (Türkiye)
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer
Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy
Drugs used in chemotherapy, such as rebeccamycin analog, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
- Trial name
- NCT00084487
- Testing
- becatecarin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Resectable, Early-stage
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
Study D9108C00002 (NeoCOAST) is a platform study assessing the effectiveness and safety of neoadjuvant durvalumab alone or in combination with novel agents in participants with resectable, early-stage (Stage I [>2cm] to IIIA)…
- Conditions
- Resectable, Early-stage, NSCLC
- Trial name
- NCT03794544
- Testing
- Durvalumab, Oleclumab, Monalizumab
- Where
- 18 sites in United States, Canada and 5 more
- Volunteers
- 84 people
- Sponsor
- MedImmune LLC
ALK Gene Rearrangement, ALK Gene Translocation
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma…
- Conditions
- ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7
- Trial name
- NCT02201992
- Testing
- Clinical Observation, Crizotinib, Laboratory Biomarker Analysis
- Where
- 1,618 sites in United States, Guam and 1 more
- Volunteers
- 166 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
This phase III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer.
- Conditions
- Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
- Trial name
- NCT03811002
- Testing
- 3-Dimensional Conformal Radiation Therapy, Atezolizumab, Biospecimen Collection
- Where
- 542 sites in United States, Japan
- Volunteers
- 544 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Feasibility of Targeted Bronchial Washing for Molecular Testing by Next Generation Sequencing in Early-stage Lung Cancer
This is a single center, clinical trial evaluating the relevance of intratumoral washing for detection of generic alteration with Next Generation Sequencing.
- Trial name
- NCT06301295
- Testing
- Ultarthin bronchoscopy with intratumoral washing
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Pusan National University Hospital
Safety Issues, Efficacy, Self
Hypofraction Radiotherapy for Limited-Stage Small Cell Lung Cancer
Concurrent chemoradiotherapy is the standard modality for locally advanced small-cell lung cancer, which could achieve median overall survival of 25 mos.
- Trial name
- NCT05523908
- Testing
- High-dose hypofraction Arm, Low-dose hypofraction Arm (Standard BED)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Anhui Provincial Hospital
Extensive-stage Small-cell Lung Cancer, Limited-stage Small-cell Lung Cancer
An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer
This phase I trial studies the side effects of 124I-hJAA-F11, and evaluates how well it works in diagnosing lung cancer. 124I-hJAA-F11 uses a known radioactive substance used in imaging called iodine 124 (124I).
- Conditions
- Extensive-stage Small-cell Lung Cancer, Limited-stage Small-cell Lung Cancer, Lung Non-Small Cell Carcinoma, Stage IIIA Lung Cancer
- Trial name
- NCT06427369
- Testing
- Radioconjugate, Positron Emission Tomography, Computed Tomography
- Sponsor
- Roswell Park Cancer Institute
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma
Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer
This phase II single-arm pilot study will evaluate the safety and preliminary efficacy of Optune-Tumor Treating Fields (TTFields) therapy as a prophylactic approach to reducing small cell lung cancer (SCLC) that has spread to the…
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8
- Trial name
- NCT03995667
- Testing
- Questionnaire Administration, Tumor Treating Fields Therapy
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- OHSU Knight Cancer Institute
Non-small Cell Lung Cancer
Multiomics Tumor Evolution Model of NSCLC
The purpose of this study is to determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be…
- Trial name
- NCT05352035
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University People's Hospital
Early-stage Peripheral Non-small Cell Lung Cancer
Personalized SBRT in Early-Stage Peripheral NSCLC
This study aims to learn about the long-term safety and effectiveness of personalized stereotactic body radiotherapy (SBRT) in patients with early-stage peripheral non-small cell lung cancer (NSCLC).
- Trial name
- NCT07167459
- Testing
- ndividualized Stereotactic Body Radiotherapy (SBRT) System
- Where
- 2 sites in China
- Volunteers
- 251 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital